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Abstract 
Peptide specific polyclonal antibodies directed against C-termini of ras p21 related GTP-binding proteins, ralA and ralB, 
were generated. To assess antibody specificity, cDNAs coding for full length ralA and ralB were expressed in Escherichia 
coli as GST fusion proteins. Western blotting analysis using enhanced chemiluminescence technique confirmed that ralA 
and ralB antibodies were specific for their respective protein. To determine the concentration and distribution, varying 
amounts of GST-ralA and GST-ralB and, human platelet particulate and cytosolic proteins were loaded during Western 
blotting. The amount of ralA and ralB proteins in the platelet particulate fraction was determined tobe 0.16 _ 0.017 txg/mg 
protein (n = 3) and 0.15 _ 0.009 txg/mg protein (n = 3) respectively. In the cytosol, only ralB protein was detected and its 
concentration was estimated to be 0.03 ___ 0.009 ~zg/mg protein (n = 3). Both ralA and ralB proteins were isoprenylated in 
the presence of [3H]mevalonolactone plus rabbit reticulocyte lysate although radioactivity incorporated into ralA was three 
times higher than that associated with the ralB protein. Addition of geranylgeranyl pyrophosphate to the reaction mixture 
inhibited incorporation of radioactivity into ralA and ralB but not cH-ras suggesting that both ralA and ralB proteins are 
geranylgeranylated. Differential distribution of ralA and ralB GTP-binding proteins in human platelets uggests a distinct 
role for each of these proteins in platelet function. 
Keywords: ralA; ralB; Ras-related GTP-binding protein; Platelet; Subcellular distribution; Concentration; Isoprenylation 
1. Introduction 
Abbreviations: GST, glutathione S-transferase; IPTG, iso- 
propyl-thio-13-~galactoside; MVA, mevalonolactone; FPP, fame- 
syl pyrophosphate; GPP, geranylgeranyl pyrophosphate; DTT, 
dithiothreitol; EDTA, ethylenediamine tetraacetic acid; PMSF, 
phenylmethylsul fonyl  fluoride; CHAPS,  3-[(3- 
cholamidopropyl)dimethyl-ammonio]- 1-pr panesulfonate; ECL, 
enhanced chemiluminescence; SDS, sodium dodecyl sulfate; 
PAGE, polyacrylamide g l electrophoresis. 
* Corresponding author at ~tddress a. Fax: + 1 (204) 7865872; 
e-mail: Bhullar @bldghsc.lan 1.umanitoba.ca. 
The existence of more than 50 genes that can 
potentially code for GTP-binding proteins of molecu- 
lar mass between 17-30 kDa has been established in
eucaryotes [1]. These proteins hare varying degree of 
homology with the ras p21 protein and are thus 
commonly referred to as members of the ras super- 
family of GTP-binding proteins [2]. In human 
platelets, the existence of more than 30 low molecu- 
lar mass GTP-binding proteins has been demon- 
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strated [3,4]. Included in this group are products of 
rac [5], G25K/CDC42Hs [5], rap [6], rab [7] and 
ral [8] genes. In addition, the existence of other low 
molecular mass GTP-binding proteins has been estab- 
lished in human platelets but the gene(s) coding for 
these has not yet been identified [8]. 
The protein coded for by the ral gene shares the 
greatest degree of homology with ras p21 [9]. The 
gene coding for the ral protein of predicted molecular 
mass of 23.5 kDa was originally isolated by screen- 
ing a simian B lymphocyte cDNA library using a 
synthetic oligonucleotide probe corresponding to a 
sequence of seven amino acids which are strictly 
conserved in all ras proteins [9]. Now ral gene has 
been cloned and sequenced from a human placental 
[5] and marine ray electric lobe [10] cDNA libraries. 
More recently, two related ral genes, raIA and ralB, 
that are 85% identical and differ essentially in their 
C-terminal sequence have been isolated from a hu- 
man [11] and rat [12] PC12 pheochromocytoma cDNA 
libraries. Northern blot analysis has demonstrated that 
both these genes are expressed in a variety of mouse 
and rat tissues with testis containing the highest level 
of ralA and ralB mRNA and brain containing high 
level of ralA and minor amounts of ralB mRNA 
[12,131. 
Information regarding the expression of ral protein 
in various tissues and cells has demonstrated that in 
platelets [8], brain [14] and kidney [15], a GTP-bind- 
ing protein with mobility of "-, 27 kDa on SDS-PAGE 
was recognized by a polyclonal antibody raised 
against recombinant ralA protein. In addition, deter- 
mination of the amino acid sequence of internal 
peptides generated from a partially purified 28 kDa 
human platelet [5] and brain [16] protein has identi- 
fied it as the product of the ral gene. However, these 
studies were unable to differentiate between the ralA 
and ralB species and thus, no information exists 
regarding the specific expression of ralA and ralB 
GTP-binding proteins in various tissues and in cells 
from which mRNA is difficult to isolate (e.g., 
platelets). 
In order to define the function of ral protein(s) in 
platelets, we have initially determined the expression, 
concentration and distribution of ralA and ralB GTP- 
binding protein(s) in platelets. In the present paper, 
we report on the generation of peptide specific anti- 
bodies against ralA and ralB GTP-binding protein 
and demonstrate hat both ralA and ralB proteins are 
expressed in human platelets. Although both ralA and 
ralB proteins were associated with the human platelet 
particulate fraction only the ralB protein was detected 
in the platelet cytosolic fraction. Recombinant ralA 
and ralB proteins were expressed in E. coli as GST 
fusion proteins and used to generate standard curves 
which were utilized to determine the concentration of
these proteins in the platelet particulate and cytosolic 
fractions. Geranylgeranylation f both ralA and ralB 
proteins in vitro was demonstrated. An abstract on 
part of this work has been published [17]. 
2. Materials and methods 
2.1. Materials 
pGEX-2T and pGEX-4T E. coli expression vec- 
tors, restriction enzymes, other molecular biology 
reagents and CNBr-activated Sepharose 4B were from 
Pharmacia Canada Ltd. (Montreal, Que., Canada). 
DH5ot and JM-109 strains of E. coli, ampicillin and 
IPTG were obtained from GIBCO-BRL (Oakville, 
Ont., Canada). Media for bacterial culture were from 
Difco Laboratories (Detroit, MI, USA). Triton-X-100, 
nitrocellulose membrane (0.2 Ixm pore size), reagents 
and prestained protein markers for SDS-PAGE were 
from Bio-Rad Laboratories (Canada) (Mississauga, 
Ont., Canada). CHAPS and Tris were obtained from 
Boehringer Mannheim (Laval, Que., Canada). High 
molecular weight protein markers for SDS-PAGE, 
PMSF, glutathione-agarose beads, thrombin, Tween 
20, FPP and GPP were from Sigma Chemical Co. 
(St. Louis, MO, USA). [e~-32p]GTP (3000 Ci /mmol)  
was from ICN Radiochemicals (Irvine, CA, USA). 
R,S-[5-3H(N)]mevalonolactone (33 Ci /mmol)  and 
Enlightning solution were from DuPont New England 
Nuclear (Boston, MA, USA). Cronex X-ray film and 
Intensifying screen was obtained from Picker Interna- 
tional (Brampton, Ont., Canada). ECL Western blot- 
ting kit was from Amersham Corp. (Oakville, Ont., 
Canada). All other reagents were of analytical grade. 
2.2. Generation of antibodies against ralA and ralB 
Peptides corresponding to C-terminal (amino acid 
192-204) of ralA (HzN-Lys-Arg-Lys-Ser-Leu-Ala- 
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Lys-Arg-Ile-Arg-Glu-Arg-Cys-COOH) and ralB 
(H 2 N-Lys-Ser-Ser-Lys-Asn-Lys-Lys-Ser-Phe-Lys- 
Glu-Arg-Cys-COOH) proteins were commercially 
synthesized. To raise antibodies, 3 mg of the peptide 
was resuspended in 1 ml of phosphate-buffered saline 
and mixed with an equal volume of Freund's com- 
plete adjuvant. After thorough mixing, the solution 
was injected subcutaneously at multiple sites in rab- 
bits. Three weeks later, 1 mg of each of the peptides 
was dissolved in 1 ml of phosphate-buffered saline 
and mixed with an equal volume of Freund's incom- 
plete adjuvant. After mixing, the solution was in- 
jected subcutaneously at multiple sites in the appro- 
priate rabbit. Three weeks later this step was repeated 
and 1 wk later a blood sample was taken and allowed 
to clot at room temperature. The serum was collected 
by centrifugation and stored at -20°C until further 
use .  
ralA protein was filled in using Klenow fragment of 
DNA polymerase I and inserted in frame into the 
refilled XmaI site present within the pGEX-2T 
polylinker. In case of ralB, the ~ 650 bp BamHI-re- 
filled SalI cDNA fragment encoding full length hu- 
man ralB protein was inserted between BamHI and 
SmaI site in the multiple cloning region of pGEX-2T. 
To express cH-ras, the ~ 900 bp EcoRI-SalI frag- 
ment coding for this protein [19] was inserted into the 
pGEX-4T vector that had been previously digested 
with EcoRI-SalI. Expression of fusion GST-ralA and 
GST-ralB proteins in recombinant clones was de- 
tected by incubating with [or-32p]GTP, nitrocellulose 
blots containing polypeptides eparated using SDS- 
PAGE [4]. Expression of GST-cH-ras was confirmed 
using the ras p21 antibody (Y13-259) in Western 
immunoblots as this protein did not bind [e~-32p]GTP 
after it had been separated using SDS-PAGE and 
blotted onto nitrocellulose (results not shown). 
2.3. Purification of peptide specific antibodies 
To purify ralA and ralB antibodies from total 
serum, the corresponding peptide affinity column was 
used. Briefly, ralA and ralB immunizing peptide was 
coupled to CNBr-activated Sepharose 4B according 
to supplier's instruction,;. The serum containing anti- 
bodies against ralA or ralB was passed through the 
appropriate peptide affinity column and washed with 
phosphate-buffered saline. To elute adsorbed antibod- 
ies, the column was washed with 0.1 M glycine (pH 
3.0) and 1 ml fractions collected. The fractions were 
immediately neutralized by the addition of 1 M Tris. 
A280 of each fraction was measured and fractions 
with the highest absorbance were pooled and stored 
at -20°C until further use. 
2.4. Expression of ralA, raIB and cH-ras in Es- 
cherichia coli 
All DNA manipulations were carried out as de- 
scribed by Sambrook et al. [18]. RalA, ralB and 
cH-ras were expressed using pGEX expression vec- 
tors in E. coli strain DH5e~ or JM-109 as fusion 
proteins coupled to the', C-terminus of the 26 kDa 
protein, glutathione S-transferase. ~ 900 bp HindlII 
cDNA fragment coding for the full length human 
2.5. Purification of fusion proteins 
GST-ralA, GST-ralB and GST-cH-ras were puri- 
fied from lysate of IPTG induced bacteria using 
glutathione-agarose beads essentially as described by 
Kaelin et al. [20], except hat Triton X-100 was used 
in buffers instead of NP-40. Beads with adsorbed 
fusion proteins were stored in NT buffer (20 mM 
Tris-HC1, pH 8.0, and 100 mM NaC1) at 4°C until 
further use. Fusion GST-ralA and GST-ralB were 
eluted from beads by incubating for 30 min at room 
temperature in a buffer containing 50 mM Tris-HC1, 
pH 8.0, and 10 mM reduced glutathione. The proteins 
released into the supernatant were collected by cen- 
trifugation for 30 s at 1300 × g in a microcentrifuge 
and the beads were further incubated three more 
times in the elution buffer. All the supernatant frac- 
tions were pooled and dialysed against 10 mM Tris- 
HC1 (pH 8.0) to remove free glutathione. To cleave 
ral proteins from GST, an aliquot of glutathione- 
agarose beads with adsorbed fusion proteins was 
incubated in equal volume of thrombin digestion 
buffer (20 mM Tris-HC1, pH 8.0, 2.5 mM CaC12, 100 
mM NaC1 and 10 Ixg/ml thrombin) for 2 h at room 
temperature with occasional shaking. The eluted 
GST-ralA, GST-ralB and GST free ralA and ralB 
proteins were stored at -20°C until further use. 
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2.6. Preparation of platelet particulate and cytosolic 
fractions 
Human platelet concentrates were obtained from 
the local Red Cross. After washing to remove con- 
taminating red blood cells [14], platelet pellet was 
lysed by sonicating (2 times, 30 s each) in a buffer 
containing 100 mM Tris-HC1, pH 7.5, 5 mM EDTA 
and 1 mM PMSF. Unbroken platelets were pelleted 
by centrifuging at 1000 X g for 10 min at 4°C. To 
prepare the cytosolic and particulate fractions, the 
platelet lysate was centrifuged at 100000 x g for 2 h 
at 4°C. The particulate fraction was resuspended in
the lysis buffer. The final cytosolic and particulate 
fractions were stored at -20°C until futher use. 
2.7. SDS-PAGE, [a- 32p]GTP-nitrocellulose blot 
overlay assay and immunoblot analysis 
SDS-polyacrylamide gel electrophoresis was per- 
formed as described in [21]. Concentration of poly- 
acrylamide in the separating el was 13%. Polypep- 
tides separated by SDS-PAGE were transferred onto 
nitrocellulose membrane using standard procedure 
[22]. Detection of proteins capable of binding [a- 
32p]GTP was carried out as described in [4,23]. Bound 
32p was detected by autoradiography (16 h at room 
temperature) using a Cronex intensifying screen. For 
immunodetection a d quantitaion of ralA or ralB, 
platelet particulate or cytosolic proteins or GST-ralA 
or GST-ralB eluted from the beads were separated by 
SDS-PAGE, transferred onto nitrocellulose and 
blocked with 5% milk powder in a buffer containing 
10 mM Tris-HC1, pH 7.5, 100 mM NaC1 and 0.1% 
Tween 20. The blots were incubated with affinity 
purified antibodies to the C-termini of ralA (1:50 
dilution, 2 h) or ralB (1:100 dilution, 1 h) in the 
above buffer. After washing (3 X 10 min in buffer 
lacking milk powder), the blots were reacted with 
goat anti-(rabbit-IgG)-horseradish peroxidase conju- 
gate (1:3000 dilution, 1 h) and the antigen-antibody 
complex visualized using ECL system. 
2.8. Isoprenylation ofralA, raIB and cH-ras proteins 
GST-ralA, GST-ralB and GST-cH-ras proteins im- 
mobilized on glutathione agarose beads were iso- 
prenylated using rabbit reticulocyte lysate as the 
source of isoprenyl transferase [24]. Briefly, 20 t.LCi 
of R,S-[5-3H(N)]mevalonolactone i  ethanol was 
dried under N 2 and resuspended in 20 ~1 of beads 
suspension containing GST or GST-fusion proteins, 
25 Ixl of reticulocyte lysate and 50 mM KC1. The 
reaction mixture was incubated at 37°C for 1.5 h. At 
the end of the incubation period, beads were washed 
three times in NT buffer, heated at 100°C in 
Laemmli's sample buffer for 3 min [21] and sub- 
jected to SDS-PAGE. Gel was incubated for 30 min 
at room temperature in 45% methanol and 7% acetic 
acid, followed by 30 min in Enlightning fluoro- 
graphic solution, dried at 80°C and an autoradiograph 
developed (4 days at -70°C using a Cronex intensi- 
fying screen). To quantitate radioactivity associated 
with proteins, the appropriate region was cut out, 5 
ml of scintillation cocktail added and radioactivity 
determined using Beckman scintillation counter 
(Model LS5801). 
2.9. Determination fprotein concentration 
Protein concentration i various platelet fractions 
was determined using the procedure of Lowry et al. 
[25] and for recombinant proteins, the Bio-Rad dye 
reagent assay based on the method of Bradford [26] 
was used. In both cases, the standard protein solution 
used contained 3% globulin and 5% human albumin. 
2.10. Scanning of immunoblots and plotting of data 
Bands were scanned and quantified using 'Image- 
Master' package (1D analysis). Data were plotted 
employing linear regression method using 'Mathe- 
matica 2' package. 
3. Results 
3.1. Expression of ralA and ralB in E. coli 
The cDNAs coding for full length human ralA and 
ralB proteins were expressed in E. coli as GST 
fusion proteins using the bacterial expression vectors, 
pGEX. When bacterial cultures started from clones 
carrying the ralA or ralB recombinant plasmid were 
induced using 0.5 mM IPTG, the synthesis of an 
~ 50 kDa protein was observed. This matched the 
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predicted molecular mas~ for GST-ralA and GST-ralB 
fusion proteins. To obtain large amounts of fusion 
proteins, a 500 ml overnight bacterial culture, grown 
at room temperature, was induced by the addition of 
0.5 mM IPTG and the culture allowed to grow for an 
additional 2 h. The fusion proteins were purified from 
cleared bacterial lysate by adsorbing them onto glu- 
tathione agarose beads. Analysis of the final fusion 
proteins using SDS-PAGE demonstrated a highly 
pure preparation of GST-ralA (Fig. 1A, lane 1) and 
GST-ralB (Fig. 1A, lane 2). 0.5-1.0 mg of fusion 
protein was obtained from 500 ml of overnight bacte- 
rial culture. When required, GST-ralA and GST-ralB 
were either eluted from the beads using glutathione 
or ralA and ralB were cleaved from the GST carrier 
protein using thrombin ~ts described in Section 2. The 
purified GST-ralA (Fig. 1B, lane 1), GST-ralB (Fig. 
1B, lane 2) and, GST free ralA (Fig. 1B, lane 3) and 
ralB (Fig. 1B, lane 4) were able to bind GTP when 
nitrocellulose blots containing proteins eparated us- 
ing SDS-PAGE were incubated with [oL-32p]GTP. 
3.2. Generation and specificity of ralA and ralB 
subtype specific antibodies 
RalA and ralB GTP-binding proteins demonstrate 
~ 85% identity at the amino acid sequence l vel and 
majority of the differences in their sequence are 
clustered in the C-terminal region [11]. Thus, we 
designed synthetic peptides corresponding to 13 
amino acids in the C-terminal region (amino acid 
192-204) of ralA and ralB. These peptides were used 
to generate polyclonal antibodies in rabbits. To assess 
antibody generation and specificity, recombinant ralA 
and ralB proteins were used in Western blots. Results 
demonstrated that ralA antibodies recognized only 
ralA (Fig. 2A, lane 1) and showed no cross reactivity 
against he ralB protein (Fig. 2A, lane 2). The ralB 
antibody did not recognize the ralA protein (Fig. 2B, 
lane 1) and was specific for ralB (Fig. 2B, lane 2). 
Thus, highly subtype specific antibodies were gener- 
ated. 
3.3. Determination of the distribution and concentra- 
tion of raIA and ralB 
Previously, we have shown using polyclonal anti- 
serum raised against recombinant ralA that human 
platelets contain ral gene product(s) of molecular 
mass of 27 kDa [8]. However, we could not differen- 
tiate between ralA and ralB proteins using these 
antibodies. The generation of subtype specific ral 
antibodies allowed us to determine the distribution 
and concentration f ralA and ralB proteins. Thus, to 
study the expression and distribution of ralA and ralB 
GTP-binding proteins in human platelets, cytosolic 
and particulate fractions were prepared as described 
in Section 2. When nitrocellulose blots containing 
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Fig. 1. Purification and GTP-binding assay of recombinant ralA and ralB. (A) 10 Ixl of glutathione-agarose beads suspension containing 
purified GST-ralA (lane 1) and GST-ralB (lane 2) were heated at 100°C for three min in Laemmli's ample buffer. After centrifuging to 
pellet the beads, supernatant was subjected to SDS-PAGE and proteins detected using Coomassie blue staining. (B) 2 Ixg of purified 
recombinant GST-ralA (lane 1), GST-ralB (lane 2), GST cartier free ralA (lane 3) and GST carrier free ralB (lane 4) were separated by 
SDS-PAGE, transferred onto nitrocellulose membrane and blot incubated with 1 txCi/ml [o~-32p]GTP as described in Section 2. The 
autoradiograph in (B) above shows proteins capable of binding [32p]GTP. The mobility of mol wt. standards i indicated on the left. 
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Fig. 2. Specificity of affinity purified antibodies. 0.2 txg of 
thrombin cleaved ralA and ralB were subjected to SDS-PAGE 
and transferred onto nitrocellulose membrane along with 
prestained protein markers. Membrane was cut into two halves 
using prestained markers as guide. One blot (A) containing ralA 
(lane 1) and ralB (lane 2) was incubated with ralA antibody and 
the second blot (B) containing ralA (lane 1) and ralB (lane 2) was 
reacted with ralB antibody as described in Section 2. The ECL 
system was used to visualize antigen-antibody complex. The 
mobility of prestained proteins is indicated on the left. 
platelet proteins separated using SDS-PAGE were 
probed with the ralA antibody, no protein with 
molecular  mass of  27 kDa was recognized in the 
cytosol ic fraction (Fig. 3A(I), lanes 1-3) .  However ,  
the ralA antibody recognized a 27 kDa protein in the 
platelet particulate fraction (Fig. 3A(I), lanes 4 -6 ) .  
When a second identical blot was incubated with the 
ralB antibody, a protein of  molecular  mass of  27 kDa 
was recognized in both the cytosol ic (Fig. 3B(I), 
lanes 1-3)  and particulate (Fig. 3B(I), lanes 4 -6 )  
fraction. 
To determine the concentrat ion of  ralA and ralB 
proteins in human platelets, varying amounts of  eluted 
recombinant  fusion proteins were separated along 
with the platelet cytosol ic and particulate proteins 
using SDS-PAGE and blotted onto the same nitro- 
cel lulose membrane.  The blots were then treated with 
1 2 3 4 5 6 
A(I) ~ 27 kDa 
1 2 3 4 5 6 
m( I I )  
4-  5 0 kD a 
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Fig. 3. Detection and determination of concentration of ralA and 
ralB in platelet fractions. 70 txg of cytosolic (AI and BI, lanes 
1-3) or particulate (AI and BI, lanes 4-6) platelet proteins 
obtained from three separate platelet preparations along with 
varying amounts (lane 1, 0.78 ng; lane 2, 1.56 ng; lane 3, 3.125 
ng; lane 4, 6.25 ng; lane 5, 12.5 ng and lane 6, 25 ng) of 
GST-ralA (All) or GST-ralB (BII) were separated using SDS- 
PAGE. After transferring the proteins onto nitrocellulose, the blot 
was probed with ralA (AI and AII) or ralB (BI and BII) antibod- 
ies. The antigen-antibody complex was visualized using ECL and 
band intensity quantitated as described in Section 2. The standard 
curve for ralA (AIII) and ralB (BIII) was generated using linear 
regression analysis with the aid of 'Mathematica 2' package. The 
concentration of ralA and ralB in platelets was obtained under 
conditions where linear relationship existed between the amount 
of protein loaded and intensity of the antigen-antibody band. 
1 2 3 4 5 6 
B(II) _ .~  4-  5o  kDa 
B(III) 
~3 .~  
u 
O~ 
I0 20 30 
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ralA (Fig. 3A(II)) or ralB (Fig. 3B(II)) antibodies and 
the antigen-antibody complex was visualized using 
ECL as described in Section 2. Standard curves were 
generated by plotting amount of ralA or ralB protein 
vs scanned intensity of antigen-antibody band (Fig. 
3A(III) and Fig. 3B(III)) and the amount of ralA and 
ralB in platelets was determined. Using this method, 
the concentration of ral proteins in the particulate 
fraction was found to be similar: 0.16 ___ 0.017 ixg/mg 
particulate protein for ra]A (n = 3) and 0.15 ___ 0.009 
ixg/mg particulate protein for ralB (n = 3). As men- 
tioned above, ralA was not detected in the platelet 
cytosolic fraction. RalB was detected in the cytosolic 
fraction and its concentration was determined to be 
0.03_ 0.009 ixg/mg of cytosolic proteins (n = 3). 
Thus, the concentration of ralB in the cytosol was 5 
times lower than that in the particulate fraction. 
However, ralB was consistently detected in the cy- 
tosolic fraction while ralA was not detected in the 
cytosol even when immunoblots were exposed to the 
X-ray film for an extended time period (results not 
shown). Although the relationship between amount of 
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Fig. 4. Isoprenylation of purified ralA and ralB. Agarose beads 
containing GST-ralA (lane 1), GST-ralB (lane 2) or GST (lane 3) 
were incubated with rabbit reticulocyte lysate and [3H]MVA as 
described under Section 2. The beads were washed, proteins 
solubilized by the addition of 25 txl of Laemmli's ample buffer 
and heated at 100°C for 3 ~in. The eluted proteins were sepa- 
rated using SDS-PAGE and treated with Enlightning fluorogra- 
phy solution as described in Section 2. The gel was dried and an 
autoradigraph developed. The mobility of prestained proteins is 
indicated on the left. 
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Fig. 5. Inhibition of [3H]MVA incorporation by FPP or GPP. 
cH-ras (lanes 1, 2, 3), ralA (lanes 4, 5, 6) and ralB (lanes 7, 8, 9) 
were expressed as fusion proteins coupled to GST and purified 
on glutathione-agarose beads. The beads were incubated with 5 
Ix Ci of [3 H]MVA (0.15 nmol) plus rabbit reticulcyte lysate (lanes 
1, 4 and 7). Reaction mixture used for lanes 2, 5 and 8 also 
contained 5-fold excess of FPP and 5-fold excess of GPP was 
added to reaction mixture of samples in lanes 3, 6 and 9. 
SDS-PAGE, fluorography and autoradiography was carried out as 
described in Section 2. The mobility of prestained proteins is 
indicated on the left. 
amounts of ral fusion proteins were used during 
immunoblotting (Fig. 3A(III) and 3B(III)), the amount 
of ralA and ralB in platelets corresponded to linear 
portion of the curve. 
3.4. Isoprenylation of ralA, ralB and cH-ras 
Attachment of an isoprenyl group (farnesyl or 
geranylgeranyl) to C-terminal cysteine has been im- 
plicated in the association of ras and ras-related 
GTP-binding proteins with the membrane [27,28]. 
Previously, ralA protein has been shown to undergo 
geranylgeranylation [24]. To establish if ralB also 
undergoes this type of post-translational modification, 
we investigated in vitro, the isoprenylation of GST- 
ralA and GST-ralB as described in Section 2. Results 
demonstrated that both ralA and ralB incorporated 
radioactivity when incubated in the presence of 
[3H]MVA and rabbit reticulocyte lysate (Fig. 4, lanes 
1 and 2). However, three times more radioactivity 
was incorporated into ralA than in ralB. No radioac- 
tivity was incorporated into the GST protein (Fig. 4, 
lane 3). To determine if ralB was modified by a 
farnesyl or a geranylgeranyl group, we investigated 
isoprenylation i  the presence of 5-fold excess of 
unlabeled FPP or GPP. We used GST-cH-ras as the 
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control protein in this experiment as it does not 
incorporate geranylgeranyl moiety and is modified 
only by the addition of a farnesyl group [27]. Results 
demonstrated that incorporation of radioactivity into 
cH-ras (Fig. 5, lane 1) was inhibited in the presence 
of an excess of FPP (Fig. 5, lane 2) and not GPP 
(Fig. 5, lane 3). This confirmed previously published 
results that cH-ras was modified exclusively by the 
addition of a farnesyl group [25]. Incorporation of 
radioactivity into ralA (Fig. 5, lane 4) was inhibited 
by the addition of unlabeled FPP (Fig. 5, lane 5) and 
GPP (Fig. 5, lane 6). In case of ralB, incorporation of 
radioactivity from [3H]MVA (Fig. 5, lane 7) was 
again inhibited in the presence of unlabeled FPP (Fig. 
5, lane 8) and GPP (Fig. 5, lane 9). Thus, from these 
results we can conclude that both ralA and ralB 
proteins were modified by the addition of a geranyl- 
geranyl group. 
4. Discussion 
Previously, the presence of ral gene product has 
been demonstrated in human platelets [8]. Now the 
existence of at least two closely related mammalian 
ral genes, ralA and raIB [11,12], has been estab- 
lished and their expression in various mouse and rat 
tissues has been determined using Northern analysis 
[12,13]. However, Northern analysis is difficult to 
perform with platelets and no subtype specific anti- 
bodies were available for ralA and ralB. Thus, it has 
not been determined whether products of both ral 
genes are expressed in the platelet and if they are, 
which ral gene product is predominant. 
In order to define the function of ral gene 
product(s) in platelets, we have initially determined 
using subtype specific antibodies the expression, dis- 
tribution and concentration of ralA and ralB GTP-bi- 
nding proteins in human platelets. The antibodies 
generated against synthetic peptides corresponding to
the C-terminal sequence (amino acid 192-204) of 
ralA and ralB, the region where these two proteins 
differ the most in their sequence [11], demonstrated 
that products of both these genes were expressed at 
approximately equal concentration i  platelets. Al- 
though little knowledge xists regarding the amount 
of various low molecular mass GTP-binding proteins 
in platelets, the value reported in the current study for 
the concentration (0.034% of total protein) of ral in 
platelets correlates very well with that reported for 
raplA in HL-60 cells [29]. However, in terms of the 
concentration of ralA or ralB versus that of raplA, 
the level of expression of ralA and ralB in platelets 
compares more closely with that of c-Ha-ras in HL-60 
cells and is lower than that reported for raplA in this 
cell [29]. 
In terms of their distribution, ralA was found to be 
associated exclusively with the platelet particulate 
fraction and majority of ralB was present in the 
particulate fraction. However, small amounts of the 
ralB protein were consistently detected in the cytoso- 
lic fraction. The reason for the differential distribu- 
tion of ralA and ralB in platelet cytosol is not clear. It 
has been established that majority of the GTP-bind- 
ing proteins in the platelet are associated with the 
particulate fraction [4-6]. However, some of these 
proteins have been detected in the cytosol. Thus, 
majority of the rab3b protein has been shown to be 
present in the platelet cytosol [7]. But it is not 
surprising to find rab3B in the cytosol as a related 
brain protein, rab3A, has been shown to be present in 
the cytosol [30]. In addition, some of the platelet rap 
proteins have been shown to redistribute after agonist 
challenge. Thus, rap2B has been shown to translocate 
from the membrane to cytoskeleton upon incubation 
of platelets with thrombin [31] and raplB is released 
into the cytosol upon phosphorylation by the cAMP- 
dependent protein kinase [32]. The related raplA 
protein with ~ 90% homology with raplB is not a 
substrate for phosphorylation a d does not translocate 
to the cytosol [32,33]. However, small amount of 
raplA was detected in the cytosol prepared from 
HL-60 cells [29]. In case of ral proteins, only the ralB 
protein was detected in the cytosol and we have not 
been able to demonstrate phosphorylation i  vitro of 
GST-ralA or GST-ralB by the catalytic subunit of 
cAMP-dependent protein kinase and have not ob- 
served any translocation of ralA or ralB proteins 
upon platelet activation (results not shown). Thus, 
these mechanisms are not likely to be responsible for 
the presence of ralB in the cytosolic fraction. 
An important additional factor that has been shown 
to play a role in the association of ras superfamily of 
GTP-binding proteins with the membrane is the at- 
tachment of an isoprenyl group to a cysteine in the 
fourth position from the C-terminus end [28]. Thus, 
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prototype of the ras superfamily, ras p21, has been 
shown to be modified by the 15-carbon farnesyl 
group [27] and, the ralA protein has been previously 
shown to be modified by the 20-carbon geranylger- 
anyl group [24]. As the sequences surrounding the 
isoprenylation site in ralA (-CCIL) and ralB (-CCLL) 
are different, we investigated isoprenylation of these 
proteins in vitro. Results demonstrated that ralA and 
ralB proteins incorporated radioactivity from 
[3H]MVA and both these proteins were modified by 
the attachment of the 20-carbon geranylgeranyl group. 
The only difference we found was that ralB incorpo- 
rated three times less radioactivity than ralA during 
the isoprenylation reaction. Although it is unlikely, 
but the probability exists that the degree of isopreny- 
lation could account for the differential distribution 
of ralA and ralB in human platelets. In addition, there 
is a possibility that ralB present in the cytosol may 
represent the unprocessed form of this protein. For 
example, in case of rap l B protein in the platelet, it 
has been demonstrated that a considerable amount of 
this protein is present in the cytosol in the unpro- 
cessed form [34]. We are currently investigating the 
possibility that cytosolic ralB is the unprocessed form 
of this protein. 
In conclusion, our results clearly establish that 
ralA and ralB GTP-binding proteins are present in 
approximately the same concentration in human 
platelets and that although, both these proteins un- 
dergo geranylgeranylation, ly the ralB protein is 
present in both the cytosolic and particulate fractions 
of the platelet. This differential distribution suggests 
a distinct role for each of these GTP-binding proteins 
in platelet function. 
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